Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 8.11% is 132% above its 5-year average of 3.49%, near the high end of its 5-year range (-0.27%–8.11%).
43.29% above its 12-month average of 5.66%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 2.01%.
RETURN ON ASSETS (ROA)
8.11%
RETURN ON ASSETS (ROA) AVG TTM
5.66%
RETURN ON ASSETS (ROA) AVG 3Y
4.50%
RETURN ON ASSETS (ROA) AVG 5Y
3.49%
RETURN ON ASSETS (ROA) AVG 10Y
4.13%
RETURN ON ASSETS (ROA) AVG 15Y
1.85%
RETURN ON ASSETS (ROA) AVG 20Y
1.13%
CURRENT VS TTM AVG
+43.29%
CURRENT VS 3Y AVG
+80.22%
CURRENT VS 5Y AVG
+132.16%
CURRENT VS 10Y AVG
+96.28%
CURRENT VS 15Y AVG
+338.38%
CURRENT VS 20Y AVG
+616.29%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+57.78%
vs the sector median at left
Boston Scientific Corporation
Market Cap
$66.96B
Return on Assets (ROA)
8.11%
TTM Avg
5.66%
3Y Avg
4.50%
5Y Avg
3.49%
Market Cap
$63.47B
Return on Assets (ROA)
3.13%
TTM Avg
2.14%
3Y Avg
2.52%
5Y Avg
0.85%
Market Cap
$58.20B
Return on Assets (ROA)
-28.75%
TTM Avg
-24.02%
3Y Avg
-10.32%
5Y Avg
-0.33%
Market Cap
$76.64B
Return on Assets (ROA)
4.08%
TTM Avg
2.99%
3Y Avg
3.50%
5Y Avg
3.82%
Market Cap
$55.01B
Return on Assets (ROA)
2.99%
TTM Avg
2.96%
3Y Avg
2.15%
5Y Avg
1.30%
Market Cap
$81.77B
Return on Assets (ROA)
10.37%
TTM Avg
11.40%
3Y Avg
12.40%
5Y Avg
16.97%
Market Cap
$50.40B
Return on Assets (ROA)
1.85%
TTM Avg
3.00%
3Y Avg
3.04%
5Y Avg
2.95%
Market Cap
$49.24B
Return on Assets (ROA)
7.25%
TTM Avg
19.91%
3Y Avg
18.29%
5Y Avg
17.04%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Boston Scientific Corporation (BSX) | $66.96B | 8.11% | 5.66% | 4.50% | 3.49% |
| Cencora, Inc. (COR)vs › | $63.47B | 3.13% | 2.14% | 2.52% | 0.85% |
| Moderna, Inc. (MRNA)vs › | $58.20B | -28.75% | -24.02% | -10.32% | -0.33% |
| Cigna Corporation (CI)vs › | $76.64B | 4.08% | 2.99% | 3.50% | 3.82% |
| Cardinal Health, Inc. (CAH)vs › | $55.01B | 2.99% | 2.96% | 2.15% | 1.30% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $81.77B | 10.37% | 11.40% | 12.40% | 16.97% |
| Becton, Dickinson and Company (BDX)vs › | $50.40B | 1.85% | 3.00% | 3.04% | 2.95% |
| Edwards Lifesciences Corporation (EW)vs › | $49.24B | 7.25% | 19.91% | 18.29% | 17.04% |
| Humana Inc. (HUM)vs › | $48.93B | 2.23% | 2.52% | 4.20% | 5.49% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $45.09B | 1.77% | -0.35% | -1.89% | -2.43% |
ROA
8.1%
ROE
14.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 6.61% |
| 2024-12-31 | 4.71% |
| 2023-12-31 | 4.53% |
| 2022-12-31 | 2.15% |
| 2021-12-31 | 3.23% |
| 2020-12-31 | -0.27% |
| 2019-12-31 | 15.38% |
| 2018-12-31 | 7.96% |
| 2017-12-31 | 0.55% |
| 2016-12-31 | 1.92% |
| 2015-12-31 | -1.32% |
| 2014-12-31 | -0.71% |
| 2013-12-31 | -0.72% |
| 2012-12-31 | -23.71% |
| 2011-12-31 | 2.07% |
| 2010-12-31 | -4.81% |
| 2009-12-31 | -4.07% |
| 2008-12-31 | -7.52% |
| 2007-12-31 | -1.59% |
| 2006-12-31 | -11.50% |
| 2005-12-31 | 7.66% |
| 2004-12-31 | 13.00% |
| 2003-12-31 | 8.28% |
| 2002-12-31 | 8.38% |
| 2001-12-31 | -1.36% |
| 2000-12-31 | 10.88% |
| 1999-12-31 | 10.39% |
| 1998-12-31 | -6.79% |
| 1997-12-31 | 7.08% |
| 1996-12-31 | 11.05% |
